Suppr超能文献

活检Gleason评分总和为4、5和6的患者在前列腺癌根治术后的结局是否存在差异?来自SEARCH数据库的结果。

Is there a difference in outcome after radical prostatectomy between patients with biopsy Gleason sums 4, 5, and 6? Results from the SEARCH database.

作者信息

Freedland S J, Amling C L, Terris M K, Presti J C, Aronson W J, Elashoff D, Kane C J

机构信息

Department of Urology, UCLA School of Medicine, Los Angeles, California 90095-1738, USA.

出版信息

Prostate Cancer Prostatic Dis. 2003;6(3):261-5. doi: 10.1038/sj.pcan.4500673.

Abstract

PURPOSE

Fewer patients newly diagnosed with prostate cancer today have biopsy Gleason sums <6 compared to several years ago. Several tables and nomograms for predicting disease recurrence after definitive therapy provide little or no discrimination between biopsy Gleason sums 4, 5, and 6. We sought to examine the significance of biopsy Gleason sum for predicting biochemical failure following radical prostatectomy (RP) for men with biopsy Gleason sums of 4, 5, and 6.

MATERIALS AND METHODS

We examined data from 988 men treated with RP between 1988 and 2002 who had biopsy Gleason sums of 4-6. Clinical and pathological variables as well as outcome information were compared between men with biopsy Gleason sums of 4-6. The log-rank and Cox proportional hazards analysis were used to determine whether biopsy Gleason sum provided unique prognostic information for men with low biopsy Gleason sums undergoing RP.

RESULTS

There was statistically significant, but overall weak correlation between biopsy Gleason sum and Gleason sum of the RP specimen (Spearman's r=0.277, P<0.001). As biopsy Gleason sum increased from 4 to 5 to 6, there was a steady rise (HR=1.31 for each one point increase in Gleason sum, Cox's model) in the risk of PSA failure (P=0.025, log-rank). On multivariate analysis comparing biopsy Gleason sum, preoperative PSA, clinical stage, year of surgery, percent of biopsy cores positive, and age for their ability to predict time to biochemical recurrence, only PSA (HR 2.09, CI 1.56-2.80, P<0.001) and biopsy Gleason sum (HR 1.33, CI 1.05-1.70, P=0.019) were significant independent predictors of PSA failure.

CONCLUSIONS

Despite weak correlation between biopsy and pathologic Gleason sum among men with biopsy Gleason sum 4-6 tumors, grade was a significant independent predictor of PSA failure following RP. In the range of 4-6, biopsy Gleason sum acted as a continuous variable for predicting PSA failure. The routine use of Gleason sums 4 and 5 to grade prostate needle biopsy specimens should not be abandoned.

摘要

目的

与几年前相比,如今新诊断出的前列腺癌患者中,活检Gleason评分总和<6的患者更少。几张用于预测根治性治疗后疾病复发的表格和列线图,对于活检Gleason评分总和为4、5和6的情况几乎没有或完全没有区分能力。我们试图研究活检Gleason评分总和对于预测活检Gleason评分总和为4、5和6的男性患者根治性前列腺切除术(RP)后生化失败的意义。

材料与方法

我们研究了1988年至2002年间接受RP治疗且活检Gleason评分总和为4 - 6的988名男性患者的数据。对活检Gleason评分总和为4 - 6的男性患者的临床和病理变量以及结局信息进行了比较。采用对数秩检验和Cox比例风险分析来确定活检Gleason评分总和是否能为接受RP的低活检Gleason评分总和男性患者提供独特的预后信息。

结果

活检Gleason评分总和与RP标本的Gleason评分总和之间存在统计学上显著但总体较弱的相关性(Spearman相关系数r = 0.277,P < 0.001)。随着活检Gleason评分总和从4增加到5再到6,PSA失败风险呈稳步上升趋势(Gleason评分每增加1分,风险比HR = 1.31,Cox模型)(P = 0.025,对数秩检验)。在多变量分析中,比较活检Gleason评分总和、术前PSA、临床分期、手术年份、活检阳性核心百分比和年龄预测生化复发时间的能力,只有PSA(风险比HR 2.09,可信区间CI 1.56 - 2.80,P < 0.001)和活检Gleason评分总和(风险比HR 1.33,可信区间CI 1.05 - 1.70,P = 于预测PSA失败的显著独立预测因素。

结论

尽管活检Gleason评分总和为4 - 6的男性患者中活检与病理Gleason评分总和之间相关性较弱,但分级是RP后PSA失败的显著独立预测因素。在4 - 6的范围内,活检Gleason评分总和可作为预测PSA失败的连续变量。不应放弃将Gleason评分4和5常规用于前列腺穿刺活检标本分级。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验